References

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2021 · External reference

Head and Neck Cancer

10.1016/s0140-6736(21)01550-6 · 2021 · External reference

Squamous Cell Carcinoma of the Oral Cavity, Larynx, Oropharynx and Hypopharynx: EHNS‐ESMO‐ESTRO Clinical Practice Guidelines for Diagnosis, Treatment and Follow‐Up

10.1016/j.annonc.2020.07.011 · 2020 · External reference

NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2025

10.6004/jnccn.2025.0007 · 2025 · External reference

Larynx Preservation in Pyriform Sinus Cancer: Preliminary Results of a European Organization for Research and Treatment of Cancer Phase III Trial

10.1093/jnci/88.13.890 · 1996 · External reference

Concurrent Chemotherapy and Radiotherapy for Organ Preservation in Advanced Laryngeal Cancer

10.1056/nejmoa031317 · 2003 · External reference

Long‐Term Results of RTOG 91‐11: A Comparison of Three Nonsurgical Treatment Strategies to Preserve the Larynx in Patients With Locally Advanced Larynx Cancer

10.1200/jco.2012.43.6097 · 2013 · External reference

Single‐Cycle Induction Chemotherapy Selects Patients With Advanced Laryngeal Cancer for Combined Chemoradiation: A New Treatment Paradigm

10.1200/jco.2005.01.2047 · 2006 · External reference

Evaluation of Swallowing Function and Aspiration in Newly Diagnosed Head and Neck Cancer Patients

10.1007/s00455-025-10888-2 · 2026 · External reference

Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer

10.1056/nejmoa071028 · 2007 · External reference

Primary Chemotherapy in Resectable Oral Cavity Squamous Cell Cancer: A Randomized Controlled Trial

10.1200/jco.2003.06.146 · 2003 · External reference

Taxane‐Cisplatin‐Fluorouracil as Induction Chemotherapy in Locally Advanced Head and Neck Cancers: An Individual Patient Data Meta‐Analysis of the Meta‐Analysis of Chemotherapy in Head and Neck Cancer Group

10.1200/jco.2012.47.7802 · 2013 · External reference

Meta‐Analysis of Chemotherapy in Head and Neck Cancer (MACH‐NC): An Update on 93 Randomised Trials and 17,346 Patients

10.1016/j.radonc.2009.04.014 · 2009 · External reference

Predictive Biomarkers for Response and Toxicity of Induction Chemotherapy in Head and Neck Cancers

10.3389/fonc.2022.900903 · 2022 · External reference

Radiotherapy Plus Cetuximab for Squamous‐Cell Carcinoma of the Head and Neck

10.1056/nejmoa053422 · 2006 · External reference

Platinum‐Based Chemotherapy Plus Cetuximab in Head and Neck Cancer

10.1056/nejmoa0802656 · 2008 · External reference

Nivolumab for Recurrent Squamous‐Cell Carcinoma of the Head and Neck

10.1056/nejmoa1602252 · 2016 · External reference

Pembrolizumab Versus Methotrexate, Docetaxel, or Cetuximab for Recurrent or Metastatic Head‐And‐Neck Squamous Cell Carcinoma (KEYNOTE‐040): A Randomised, Open‐Label, Phase 3 Study

10.1016/s0140-6736(18)31999-8 · 2019 · External reference

Pembrolizumab Alone or With Chemotherapy Versus Cetuximab With Chemotherapy for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (KEYNOTE‐048): A Randomised, Open‐Label, Phase 3 Study

10.1016/s0140-6736(19)32591-7 · 2019 · External reference

The Society for Immunotherapy of Cancer Consensus Statement on Immunotherapy for the Treatment of Squamous Cell Carcinoma of the Head and Neck (HNSCC)

10.1186/s40425-019-0662-5 · 2019 · External reference

Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus‐Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial

10.1158/1078-0432.ccr-20-1695 · 2020 · External reference

Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open‐Label Randomized Clinical Trial

10.1001/jamaoncol.2020.2955 · 2020 · External reference

Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable Local‐Regionally Advanced Head and Neck Squamous Cell Carcinoma

10.1158/1078-0432.ccr-21-3351 · 2022 · External reference

Pathologic Treatment Effect and Survival in HPV‐Negative HNSCC Following Neoadjuvant Nivolumab

10.1001/jamaoto.2025.1707 · 2025 · External reference

Perioperative Immunotherapy in Resectable HNSCC: Biological Rationale to Practical Multidisciplinary Implementation

10.3389/fonc.2026.1799437 · 2026 · External reference

Neoadjuvant Chemotherapy Plus Anlotinib in the Treatment of Resectable Head and Neck Squamous Cell Carcinoma: A Pilot Phase II Trial

10.1002/cac2.70006 · 2025 · External reference

Real‐World Study of Later‐Line Anlotinib in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

10.1111/odi.15290 · 2025 · External reference

Pharmacokinetics and Disposition of Anlotinib, an Oral Tyrosine Kinase Inhibitor, in Experimental Animal Species

10.1038/aps.2017.199 · 2018 · External reference

Effective Low‐Dose Anlotinib Induces Long‐Term Tumor Vascular Normalization and Improves Anti‐PD‐1 Therapy

10.3389/fimmu.2022.937924 · 2022 · External reference

Anlotinib as a Promising Inhibitor on Tumor Growth of Oral Squamous Cell Carcinoma Through Cell Apoptosis and Mitotic Catastrophe

10.1186/s12935-020-01721-x · 2021 · External reference

Suppressed Mitochondrial Respiration via NOX5‐Mediated Redox Imbalance Contributes to the Antitumor Activity of Anlotinib in Oral Squamous Cell Carcinoma

10.1016/j.jgg.2021.06.014 · 2021 · External reference

SOD2 Confers Anlotinib Resistance via Regulation of Mitochondrial Damage in OSCC

10.1111/odi.14404 · 2024 · External reference

Ten Years of Anti‐Vascular Endothelial Growth Factor Therapy

10.1038/nrd.2015.17 · 2016 · External reference

Normalizing Tumor Vasculature With Anti‐Angiogenic Therapy: A New Paradigm for Combination Therapy

10.1038/nm0901-987 · 2001 · External reference

Effect of Anlotinib as a Third‐Line or Further Treatment on Overall Survival of Patients With Advanced Non‐Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial

10.1001/jamaoncol.2018.3039 · 2018 · External reference

Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients With Refractory Metastatic Soft‐Tissue Sarcoma

10.1158/1078-0432.ccr-17-3766 · 2018 · External reference

New Response Evaluation Criteria in Solid Tumours: Revised RECIST Guideline, Version 1.1

10.1016/j.ejca.2008.10.026 · 2009 · External reference

Pathological Response After Neoadjuvant Chemotherapy in Resectable Non‐Small‐Cell Lung Cancers: Proposal for the Use of Major Pathological Response as a Surrogate Endpoint

10.1016/s1470-2045(13)70334-6 · 2014 · External reference

Pathologic Features of Response to Neoadjuvant Anti‐PD‐1 in Resected Non‐Small‐Cell Lung Carcinoma: A Proposal for Quantitative Immune‐Related Pathologic Response Criteria (irPRC)

10.1093/annonc/mdy218 · 2018 · External reference

Neoadjuvant PD‐1 Blockade in Resectable Lung Cancer

10.1056/nejmoa1716078 · 2018 · External reference

Neoadjuvant Nivolumab Plus Chemotherapy in Resectable Lung Cancer

10.1056/nejmoa2202170 · 2022 · External reference

The European Organization for Research and Treatment of Cancer QLQ‐C30: A Quality‐Of‐Life Instrument for Use in International Clinical Trials in Oncology

10.1093/jnci/85.5.365 · 1993 · External reference

Validity and Reliability of the Eating Assessment Tool (EAT‐10)

10.1177/000348940811701210 · 2008 · External reference

Initial Psychometric Assessment of a Functional Oral Intake Scale for Dysphagia in Stroke Patients

10.1016/j.apmr.2004.11.049 · 2005 · External reference